Transitioning pharmacologic therapy from oral agents to insulin for type 2 diabetes

References

• Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR for the U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25: 330–6
   Google Scholar
• Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000;108(Suppl 6a):15S–22S
   Google Scholar
• Campbell RK, White JR Jr. Insulin therapy in type 2 diabetes. J Am Pharm Assoc (Wash) 2002;42:602–11
   PubMedGoogle Scholar
• Scheen AJ. Clinical study of the month: Toxicity of hyperglycemia in intensive care and beneficial effects of optimized insulin therapy. Rev Med Liege 2001; 56:859–861
   PubMedGoogle Scholar
• Park S and Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 2003;19: 124–30
   Google Scholar
• Buchanan TA. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther 2003;25(Suppl B):B32–46
   Google Scholar
• McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA. Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 2001;18:10–6
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Kendall DM, Franz MJ, Rubenstein AH. Management of type 2 diabetes: a systematic approach to meeting the standards of care. II: oral agents, insulin, and management of complications. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 4th ed. Philadelphia, PA: W.B. Saunders Co.; 2001. p. 821–35
   Google Scholar
• DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318–68
   PubMed Web of Science ®Google Scholar
• Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863–70
   Google Scholar
• Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR). Drugs 1999;58\(Suppl 1): 7–10; discussion 75–82
   Google Scholar
• Bloomgarden ZT. Insulin resistance: current concepts. Clin Ther 1998;20:216–31; discussion 215
   Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15: 539
   Google Scholar
• Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106:3143
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Clinical practice recommendations 2004. Diabetes Care 2004;27(Suppl 1):S1–S150
   Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287: 356
   Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709
   PubMed Web of Science ®Google Scholar
• Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990;132:501–13
   PubMed Web of Science ®Google Scholar
• Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13:610–30
   PubMed Web of Science ®Google Scholar
• McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999;42:128–38
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–17
   PubMed Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823–8
   PubMed Web of Science ®Google Scholar
• Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993;36: 1175–84
   Google Scholar
• Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000;23:45–50
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Clinical practice recommendations 2003. Diabetes Care 2003;26(Suppl 1):S1–S156
   Google Scholar
• American College of Endocrinology, American Association of Clinical Endocrinologists. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract 2002;8(Suppl 1):5–11
   PubMedGoogle Scholar
• American Association of Clinical Endocrinologists, American College of Endocrinology. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management – 2002 update. Endocr Pract 2002;8(Suppl 1):41–82
   Google Scholar
• American Diabetes Association. Clinical practice recommendations 2002. Diabetes Care 2002;25(Suppl 1):S1–S147
   PubMedGoogle Scholar
• Rohlfing CL, Wiedmeyer H-M, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25: 275–8
   Google Scholar
• Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996;156:259–64
   Google Scholar
• Wyne KL, Drexler AJ, Miller JL, Bell DS, Braunstein S, Nuckolls JG. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. Postgrad Med 2003; May (Spec No.):63–72
   Google Scholar
• Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 2001;63:1747–56
   PubMed Web of Science ®Google Scholar
• Davis SN. Advances in oral therapy for type 2 diabetes. Postgrad Med 2000; May (Spec No.):16–20
   Google Scholar
• Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997;26:511–22
   PubMed Web of Science ®Google Scholar
• Dunn CJ, Faulds D. Nateglinide. Drugs 2000;60:607–15
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992;15:755–72
   PubMed Web of Science ®Google Scholar
• Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000;355:1008–10
   PubMed Web of Science ®Google Scholar
• Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003;78:1088–91
   PubMed Web of Science ®Google Scholar
• Bischoff H. Pharmacology of a-glucosidase inhibition. Eur J Clin Invest 1994;24(Suppl 3):3–10
   PubMed Web of Science ®Google Scholar
• Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin–glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002;19:673–80
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Insulins: chart depicting the different types of insulin. Available from http://www.diabetes.org/community/forecast/ResourceGuide2003/2003ResourceGuide_PDF/Insulin.pdf. [Accessed 25 November 2003]
   Google Scholar
• American Diabetes Association. Insulin administration. Diabetes Care 2002;25:S112–S115
   Google Scholar
• Burge MR, Schade DS. Insulins. Endocrinol Metab Clin North Am 1997;26:575–98
   PubMed Web of Science ®Google Scholar
• Holleman F, Hoekstra JBL. Insulin lispro. N Engl J Med 1997;337:176–83
   PubMed Web of Science ®Google Scholar
• Barnett AH, Owens DR. Insulin analogues. Lancet 1997;349:47–51
   PubMed Web of Science ®Google Scholar
• Hirsch IB. Intensive treatment of type 1 diabetes. Med Clin North Am 1998;82:689–719
   PubMed Web of Science ®Google Scholar
• Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet 2002;41:1043–57
   PubMed Web of Science ®Google Scholar
• Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000;56:399–403
   Google Scholar
• Rosenstock J, Schwartz SL, Clark Jr. CM, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24: 631–6
   Google Scholar
• Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644–9
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758–67
   PubMed Web of Science ®Google Scholar
• Riddle MC, Schneider J for the Glimepiride Combination Group. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998;21:1052–7
   Google Scholar
• Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J for the Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24: 1226–32
   Google Scholar
• Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S for the Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56: 251–7
   Google Scholar
• American Association of Diabetes Educators. National standards for diabetes self-management education. Available from www.aadenet.org/AboutAADE/about_frame.html. [Accessed 18 November 2002]
   Google Scholar
• Murray DP, Keenan P, Gayer E, et al. A randomized trial of the efficacy and acceptability of a pen injector. Diabet Med 1988;5:750–4
   PubMed Web of Science ®Google Scholar
• Dunbar JM, Madden PM, Gleeson DT, Fiad TM, McKenna TJ. Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care 1994;17:874–8
   Google Scholar
• Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307–35
   PubMed Web of Science ®Google Scholar
• Holman RR, Turner RC. The basal plasma glucose: a simple relevant index of maturity-onset diabetes. Clin Endocrinol (Oxf) 1981;14:279–86
   PubMed Web of Science ®Google Scholar
• Edelman SV, Henry RR. Insulin therapy. Diagnosis and management of type 2 diabetes. 5th ed. Caddo, Oklahoma: Professional Communications, Inc.; 2002. p. 121–48
   Google Scholar
• Ahmann AJ, Riddle MC. Insulin therapy in type 2 diabetes mellitus. In: Leahy JL, Cefalu WT, editors. Insulin therapy. New York (NY): Marcel Dekker, Inc.; 2002. p. 113–25
   Google Scholar
• Riddle MC, Rosenstock J, Gerich J on behalf of the Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26: 3080–6
   Google Scholar
• Fritsche A, Schweitzer MA, Häring H-U and the 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2003;138: 952–9
   Google Scholar
• Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group. The UK Prospective Diabetes Study. Ann Med 1996;28:439–44
   Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281: 2005–12
   Google Scholar
• United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83–8
   PubMed Web of Science ®Google Scholar
• Texas Diabetes Council. Insulin algorithm for type 2 diabetes mellitus in children and adults. Available from http://www.tdh.state.tx.us/diabetes/pdf/algorithms/inst2.pdf. [Accessed 4 November 2003]
   Google Scholar
• UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. UK Prospective Diabetes Study Group. Diabetes Care 1998;21:87–92
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM for the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541–9
   Google Scholar
• Hermann LS, Scherstén B, Bitzén P-O, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100–9
   PubMed Web of Science ®Google Scholar
• Chiasson J-L, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994;121:928–35
   Google Scholar
• Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW for the Troglitazone Study Group. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care 1998;21:1462–9
   Google Scholar
• Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10–7
   PubMed Web of Science ®Google Scholar
• Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119–24
   PubMed Web of Science ®Google Scholar
• Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695–702
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 1998;21:2050–5
   PubMed Web of Science ®Google Scholar
• Rendell MS, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications 2003;17: 211–7
   Google Scholar